NCT04983901View on ClinicalTrials.gov

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
DRUG

Imipenem/Cilastatin/Relebactam

Given IV

DRUG

Cefepime

Given IV

DRUG

Meropenem

Given IV

DRUG

Piperacillin-Tazobactam

Given IV

DRUG

Vancomycin

Given IV

DRUG

Daptomycin

Given IV

DRUG

Linezolid

Given IV or PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | Biotech Hunter | Biotech Hunter